Secondary interstitial lung disease in childhood and adulthood associated with a systemic disease

Secondary interstitial lung disease (ILD) in childhood and adulthood associated with a systemic disease refers to a broad category of lung disorders in which the interstitium (the tissue and space around the air sacs of the lungs) becomes inflamed, scarred, or otherwise damaged as a consequence of an underlying systemic condition. This category encompasses ILD that develops secondary to connective tissue diseases (such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, dermatomyositis, and mixed connective tissue disease), vasculitis syndromes, sarcoidosis, inflammatory bowel disease, and other multisystem disorders. The lung involvement is not the primary disease but rather a manifestation of the broader systemic process. Key symptoms include progressive shortness of breath (dyspnea), chronic dry cough, reduced exercise tolerance, fatigue, and in some cases, clubbing of the fingers. Patients may also exhibit symptoms related to their underlying systemic disease, such as joint pain, skin changes, muscle weakness, or multi-organ involvement. Pulmonary function testing typically reveals a restrictive pattern with reduced diffusing capacity, and high-resolution CT imaging of the chest may show ground-glass opacities, reticular patterns, honeycombing, or other characteristic findings depending on the specific type of ILD and the underlying condition. Treatment is directed at both the underlying systemic disease and the lung involvement. Immunosuppressive therapies, including corticosteroids, mycophenolate mofetil, azathioprine, cyclophosphamide, and rituximab, are commonly used depending on the specific systemic disease and severity of lung involvement. Antifibrotic agents such as nintedanib have been approved for progressive fibrosing ILD regardless of underlying cause. Supportive measures include supplemental oxygen, pulmonary rehabilitation, and in severe end-stage cases, lung transplantation may be considered. Early detection and management of the pulmonary component is critical to preserving lung function and quality of life.

Common questions about Secondary interstitial lung disease in childhood and adulthood associated with a systemic disease